One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis

BACKGROUND: Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS: We conducted a randomized, open-label, phase 3 noninferiority tria...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Swindells, S., Ramchandani, R., Gupta, A., Benson, C.A., Leon-Cruz, J., Mwelase, N., Jean Juste, M.A., Lama, J.R., Valencia, J., Omoz-Oarhe, A., Supparatpinyo, K., Masheto, G., Mohapi, L., da Silva Escada, R.O., Mawlana, S., Banda, P., Severe, P., Hakim, J., Kanyama, C., Langat, D., Moran, L., Andersen, J., Fletcher, C.V., Nuermberger, E., Chaisson, R.E.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563914/
https://ncbi.nlm.nih.gov/pubmed/30865794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1806808
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars